company background image
TGTX logo

TG Therapeutics NasdaqCM:TGTX Stock Report

Last Price

US$15.57

Market Cap

US$2.3b

7D

1.3%

1Y

4.8%

Updated

27 Mar, 2024

Data

Company Financials +

TG Therapeutics, Inc.

NasdaqCM:TGTX Stock Report

Market Cap: US$2.3b

TGTX Stock Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

TGTX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth6/6
Past Performance3/6
Financial Health3/6
Dividends0/6

TG Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TG Therapeutics
Historical stock prices
Current Share PriceUS$15.57
52 Week HighUS$35.67
52 Week LowUS$6.46
Beta2.32
1 Month Change16.54%
3 Month Change-11.63%
1 Year Change4.85%
3 Year Change-67.70%
5 Year Change87.14%
Change since IPO1,270.29%

Recent News & Updates

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Mar 25
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

TG Therapeutics: Briumvi Growth Story Appears Intact

Mar 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Recent updates

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Mar 25
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

TG Therapeutics: Briumvi Growth Story Appears Intact

Mar 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Jan 10

Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Jan 04
Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

Nov 24
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Sep 30
TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Aug 03
Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jul 19
Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Apr 13
Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

Jan 02
Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

TG Therapeutics: Elucidating The Upcoming Binary

Oct 09

TG Therapeutics: We Are Just Hanging In There

Sep 21

Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

Sep 07
Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials

Aug 25

TG Therapeutics Q2 2022 Earnings Preview

Aug 05

TG Therapeutics And Ublituximab: From Icing To Lifeline

Jul 08

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jun 06
Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

TG Therapeutics: I May Double Down Again

Apr 18

Ublituximab In MS Is The Heart Of TG Therapeutics, And The Heart Is Safe

Feb 08

TG Therapeutics: Double Down On Partial Clinical Hold Non-Issue

Jan 28

TG Therapeutics: Elucidating The Upcoming Binary Event

Dec 27

Shareholder Returns

TGTXUS BiotechsUS Market
7D1.3%0.9%0.4%
1Y4.8%10.3%28.8%

Return vs Industry: TGTX underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: TGTX underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is TGTX's price volatile compared to industry and market?
TGTX volatility
TGTX Average Weekly Movement11.9%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: TGTX's share price has been volatile over the past 3 months.

Volatility Over Time: TGTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1993264Mike Weisshttps://www.tgtherapeutics.com

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.

TG Therapeutics, Inc. Fundamentals Summary

How do TG Therapeutics's earnings and revenue compare to its market cap?
TGTX fundamental statistics
Market capUS$2.25b
Earnings (TTM)US$12.67m
Revenue (TTM)US$233.66m

177.9x

P/E Ratio

9.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TGTX income statement (TTM)
RevenueUS$233.66m
Cost of RevenueUS$14.13m
Gross ProfitUS$219.53m
Other ExpensesUS$206.86m
EarningsUS$12.67m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.088
Gross Margin93.95%
Net Profit Margin5.42%
Debt/Equity Ratio62.6%

How did TGTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.